Abstract
The ganciclovir implant is a sustained-release intraocular drug delivery system used to treat cytomegalovirus retinitis that provides a high and steady-state concentration of the drug in the vitreous cavity over a period of 7-8 months. Randomized, controlled clinical trials have demonstrated a superior efficacy of the implant compared with intravenous ganciclovir. Severe adverse events associated with the implant are uncommon, though potentially blinding. In addition, the implant provides no protection against second-eye or visceral cytomegalovirus retinitis infections. This review summarizes the clinical indications for and complications associated with the ganciclovir implant.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 421-427 |
| Number of pages | 7 |
| Journal | Expert review of medical devices |
| Volume | 2 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2005 |
Keywords
- Cidofovir
- Cytomegalovirus DNA polymerase
- Cytomegalovirus retinitis
- Endophthalmitis
- Foscarnet
- Ganciclovir
- Ganciclovir implant
- Retinal detachment
- Viral resistance
ASJC Scopus subject areas
- Surgery
- Biomedical Engineering